Azacitidine for Elderly AML Patients Ineligible for Intensive Chemotherapy

Introduction to Treatment Options

The National Comprehensive Cancer Network recommends venetoclax combined with azacitidine as the preferred first-line treatment for elderly AML patients ineligible for intensive chemotherapy, offering a CR/CRi rate of 67% and median overall survival of 17.5 months 1

The American College of Cardiology and the National Comprehensive Cancer Network suggest that venetoclax (400 mg orally daily) combined with azacitidine (75 mg/m² subcutaneously or IV for 7 days every 28 days) represents the current standard of care for this patient population, with FDA approval for patients aged ≥75 years or those with comorbidities, including renal impairment 1, 2, 3
The National Comprehensive Cancer Network guidelines recommend hypomethylating agents, such as azacitidine, as preferred monotherapy for patients declining or unable to receive combination therapy, with median overall survival of 8.9 months in AML-MRC patients and 24.5 months in higher-risk MDS/AML 2, 3

Glasdegib plus low-dose cytarabine improved median OS to 8.8 months versus 4.9 months with low-dose cytarabine alone, particularly benefiting patients with favorable/intermediate-risk cytogenetics 4
Low-dose cytarabine alone provides median OS of approximately 5 months but has very poor activity in adverse-risk cytogenetics and should be avoided in that subgroup 5

The National Comprehensive Cancer Network and the American Society of Clinical Oncology emphasize the importance of renal function monitoring, with CKD stage 3 requiring specific dose adjustments, and clofarabine must be avoided entirely in patients with impaired renal function 1
Cardiac monitoring is essential given the patient's comorbidities, with heart failure requiring careful fluid management during HMA administration 1

For FLT3-mutated AML, azacitidine combined with sorafenib or gilteritinib achieves a CR/CRi rate of 67% in early trials 3, 6
For IDH1-mutated AML, ivosidenib (500 mg daily) achieves a CR/CRh rate of 41.2%, or venetoclax/HMA with remission rates >70% 2, 3
For IDH2-mutated AML, enasidenib (100 mg daily) achieves a CR/CRi rate of 43%, or venetoclax/HMA 2, 3

The National Comprehensive Cancer Network recommends mandatory supportive measures, including transfusion support for anemia and thrombocytopenia 2
Infection prophylaxis is essential, as febrile neutropenia occurs in 30-61% of patients on venetoclax/HMA 1
Tumor lysis syndrome prevention with venetoclax-based regimens is crucial 1
Hydroxyurea is recommended for cytoreduction if presenting with hyperleukocytosis 2, 7

The National Comprehensive Cancer Network advises against using best supportive care alone when low-intensity therapy is feasible, as 79.7% of untreated elderly AML patients die within 60 days, compared to median survival of 3.6 months even with supportive care only 4, 8
Standard-dose intensive chemotherapy should not be used in patients with CKD stage 3, heart failure, and advanced age, as the 30-day mortality can reach 14% or higher in this population 9